文献速递糖尿病

单剂二甲双胍增强2型糖尿病患者胆汁酸诱导的胰高血糖素样肽-1分泌

Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes.
PubMed 文献 · J Clin Endocrinol Metab · 2017-01-01

在丹麦根措夫特医院开展的一项随机、安慰剂对照、双盲交叉研究中,15例接受二甲双胍治疗的2型糖尿病患者完成4个实验日。单剂二甲双胍进一步增强了胆汁酸介导的GLP-1分泌(P=0.02),而单用二甲双胍未较安慰剂增加血浆GLP-1浓度(P=0.17)。二甲双胍在伴或不伴缩胆囊素诱导的胆囊排空时均较安慰剂降低血糖波动(均P=0.02),未观察到GLP-1介导的胰岛素分泌诱导或胰高血糖素抑制。

要点

  • 单剂二甲双胍可增强缩胆囊素诱导胆囊排空时的GLP-1分泌反应(P=0.02)。
  • 单用二甲双胍未较安慰剂增加血浆GLP-1浓度(P=0.17)。
  • 二甲双胍伴或不伴缩胆囊素诱导胆囊排空均较安慰剂降低血糖波动(均P=0.02)。

核心结论

  • 二甲双胍增强了2型糖尿病患者对缩胆囊素诱导胆囊排空产生的GLP-1反应,而在此急性设定下未观察到对胰岛素或胰高血糖素分泌的衍生效应。

研究设计与样本

  • 随机、安慰剂对照、双盲交叉研究,在丹麦根措夫特医院糖尿病研究中心开展。
  • 15例接受二甲双胍治疗的2型糖尿病患者,所有参与者均完成研究。
  • 4个实验日按随机顺序给予1500 mg二甲双胍或安慰剂,联合缩胆囊素(0.4 pmol × kg-1 × min-1)或生理盐水静脉输注。

主要发现

  • 单剂二甲双胍进一步增强了胆汁酸介导的GLP-1分泌诱导(P=0.02)。
  • 单用二甲双胍与安慰剂相比未增加血浆GLP-1浓度(P=0.17)。
  • 二甲双胍联合缩胆囊素诱导胆囊排空时较安慰剂降低血浆葡萄糖波动(P=0.02)。
  • 二甲双胍不联合缩胆囊素诱导胆囊排空时亦较安慰剂降低血浆葡萄糖波动(P=0.02)。
  • 未观察到GLP-1介导的胰岛素分泌诱导或胰高血糖素抑制。

关键数值与推荐

  • 主要结局指标为血浆GLP-1波动,以基线扣除后的曲线下面积测量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Despite a position as the first-line pharmacotherapy in type 2 diabetes, the glucose-lowering mechanisms of metformin remain to be fully clarified. Gut-derived modes of action, including suppression of bile acid reabsorption and a resulting increase in glucagon-like peptide-1 (GLP-1) secretion, have been proposed. OBJECTIVE: The aim of this study was to assess the GLP-1 secretory and glucometabolic effects of endogenously released bile, with and without concomitant single-dose administration of metformin in patients with type 2 diabetes. DESIGN: Randomized, placebo-controlled, and double-blinded crossover study. SETTING: This study was conducted at Center for Diabetes Research, Gentofte Hospital, Denmark. PATIENTS: Fifteen metformin-treated patients with type 2 diabetes; all participants completed the study. INTERVENTIONS: Four experimental study days in randomized order with administration of either 1500 mg metformin or placebo in combination with intravenous infusion of cholecystokinin (0.4 pmol × kg-1 × min-1) or saline. MAIN OUTCOME MEASURE: Plasma GLP-1 excursions as measured by baseline-subtracted area under the curve. RESULTS: Single-dose metformin further enhanced bile acid-mediated induction of GLP-1 secretion (P = 0.02), whereas metformin alone did not increase plasma GLP-1 concentrations compared with placebo (P = 0.17). Metformin, both with (P = 0.02) and without (P = 0.02) concomitant cholecystokinin-induced gallbladder emptying, elicited reduced plasma glucose excursions compared with placebo. No GLP-1-mediated induction of insulin secretion or suppression of glucagon was observed. CONCLUSIONS: Metformin elicited an enhancement of the GLP-1 response to cholecystokinin-induced gallbladder emptying in patients with type 2 diabetes, whereas no derived effects on insulin or glucagon secretion were evident in this acute setting.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Brønden A, Albér A, Rohde U, et al. Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2017. PMID: 28938439. doi:10.1210/jc.2017-01091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。